Vancouver, British Columbia–(Newsfile Corp. – July 11, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) (“Emerald” or the “Company”) has reported financial results for...
Company also provides bi-weekly MCTO status update Vancouver, British Columbia–(Newsfile Corp. – July 4, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) (“Emerald” or...
Vancouver, British Columbia–(Newsfile Corp. – June 16, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) (“Emerald” or the “Company”) is providing a default status...
Vancouver, British Columbia–(Newsfile Corp. – June 3, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) (“Emerald” or the “Company“) is providing a status report in accordance with...
Vancouver, British Columbia–(Newsfile Corp. – May 16, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) (“Emerald” or the “Company“) is providing a default status report in accordance...
Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022 Preclinical studies...
Vancouver, British Columbia–(Newsfile Corp. – May 6, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) (“Emerald” or the “Company”) announced today that it has...
Vancouver, British Columbia–(Newsfile Corp. – April 28, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) (“Emerald” or the “Company”) reports that it anticipates it will...
Vancouver, British Columbia–(Newsfile Corp. – January 11, 2022) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) (“Emerald”) has entered into a binding term sheet to sell...
Vancouver, British Columbia–(Newsfile Corp. – December 31, 2021) – Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) (“Emerald”) has announced the results of voting at its...